The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Discovery of microRNAs in tumor tissue predictive of time to progression and overall survival in patients with colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
Mogens Karsboel Boisen
Research Funding - Roche
Christian Dehlendorff
No relevant relationships to disclose
Dorte Linnemann
No relevant relationships to disclose
Kristina Ranc
No relevant relationships to disclose
Benny V. Jensen
Consultant or Advisory Role - Roche
Honoraria - Roche
Estrid V. H√łgdall
No relevant relationships to disclose
Jim S. Larsen
No relevant relationships to disclose
Svend Erik Nielsen
No relevant relationships to disclose
Klaus Kaae Andersen
No relevant relationships to disclose
Julia S. Johansen
Honoraria - Roche